Alkermes plc buy melinda
Start price
19.06.17
/
50%
€51.55
Target price
05.07.17
€54.12
Performance (%)
5.28%
End price
05.07.17
€54.27
Summary
This prediction ended on 05.07.17 with a price of €54.27. With a performance of 5.28%, the BUY prediction by melinda for Alkermes plc closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | 4.444% | 4.444% | -15.060% | 10.567% |
| iShares Core DAX® | 0.048% | 1.311% | 11.378% | 62.793% |
| iShares Nasdaq 100 | 1.601% | -0.902% | 7.287% | 90.940% |
| iShares Nikkei 225® | 3.057% | 12.947% | 33.767% | 70.774% |
| iShares S&P 500 | 0.820% | 0.703% | 4.930% | 61.763% |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
genehmigt (FDA)
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.